Agios Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism. Agios is building a robust platform integrating metabolomics, genetics, biochemistry and microscopy to enable biomarker and target identification. Agios’ platform of differential cellular metabolism of diseased cells relative to normal cells will also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases.

Doug Cole is on the Board of Directors.